The next scheduled trial accusing Monsanto’s weed killer Roundup of causing cancer has been delayed, said Bayer AG, which acquired Monsanto last year.
The trial was set to begin Oct. 15 in St. Louis City, but was delayed as mediator Ken Feinberg works to negotiate a settlement between the company and hundreds of plaintiffs who claim exposure to Roundup caused them to develop non-Hodgkin’s lymphoma. Bayer has faced three trials to date, all of which have ended in multimillion-dollar verdicts in favor of the plaintiffs.
“With the change in the trial schedule and no trial dates set through the rest of the year, the appeals of the three completed trials will be a significant focus of the litigation in the months ahead,” Bayer said in a statement.
The Circuit Court of the City of St. Louis set a Feb. 10, 2020, date for a status conference to reevaluate the case.
Bayer faces about 18,400 lawsuits alleging its herbicide Roundup causes cancer. The culprit, they say, is its active ingredient glyphosate, which the World Health Organization’s International Agency for Research on Cancer in 2015 classified as a “probable carcinogen,” referencing cases of non-Hodgkin’s lymphoma in farmers exposed to glyphosate.
Bayer has held firm on its stance that glyphosate is safe. However, the hefty verdicts have adversely impacted the company share price, which reached a near-seven-year low in May, following a $2.055 billion verdict awarded to an elderly couple, both of whom were diagnosed with non-Hodgkin’s lymphoma.
We are investigating cases involving non-Hodgkin lymphoma related to the commercial application of Roundup/glyphosate. For more information or to discuss a possible claim, contact John Tomlinson, Danielle Ingram, Michael Dunphy or Rhon Jones.